HI SR172

Request the Department of Health to establish a Medicinal Psilocybin and Psilocin Working Group to examine federal, state, and local laws regarding medicinal use of psilocybin and psilocin.

Working group to review medical, psychological, and scientific studies on the safety and efficacy of psilocybin and psilocin for treating mental health conditions including addiction, depression, anxiety disorders, and end-of-life psychological distress.

If feasible, develop a long-term strategic plan to ensure availability of medicinal psilocybin and psilocin products that are safe, accessible, and affordable for adults 21 years of age or older.

Working group membership to include the Director of Health (as chairperson), Attorney General, University of Hawaii faculty, legislative committee chairs, clinical practitioners, and representatives from the Drug Policy Forum of Hawaii, Clarity Project, Hawaii Psychiatric Medical Association, and the public with psychedelics industry experience; maximum 15 members.

Submit preliminary report to the Legislature by twenty days prior to the 2022 Regular Session and final report with proposed legislation by twenty days prior to the 2023 Regular Session; working group to be dissolved on July 1, 2023.